세계의 크론병 치료 시장 : 치료, 제형, 연령층, 최종 용도별 예측(2024-2032년)

Crohn's Disease Treatment Market is anticipated to record 4% CAGR during 2024-2032, backed by the increasing global prevalence of inflammatory bowel disease (IBD). According to the 2023 fact sheet by Crohn's & Colitis Foundation, around 1.6 to 3.1 million Americans are affected by IBD. Improved awareness and diagnostics are leading to more cases being identified, which boosts the demand for effective treatments. Advances in medical research and technology have also led to new therapies and biologics, offering hope for patients. For example, in July 2024, the FDA granted approval for ustekinumab-ttwe, a component of Stelara (Janssen Immunology), for all its indications, including severe psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Additionally, the focus on personalized medicine is changing how Crohn's disease is treated. As the understanding of the disease's pathophysiology improves, treatments are becoming more tailored to individual genetic and molecular profiles. This approach improves treatment effectiveness and patient outcomes, further driving market growth.

The overall Crohn's disease treatment industry is classified based on treatment, dosage form, age group, end-use, and region.

The nutritional therapy segment will gain significant traction through 2032, due to its critical role in managing symptoms and improving patient outcomes. Nutritional therapy helps address malabsorption issues, maintain proper nutritional status, and reduce inflammation. Customized dietary plans, such as enteral nutrition and exclusion diets, are increasingly recognized for their potential to induce remission and complement pharmacological treatments. This approach not only supports overall health and quality of life but also reduces reliance on medications, which can have adverse effects.

The pediatric segment is poised to hold a notable market share by 2032, backed by the improved awareness of disease and benefits of early diagnosis. Crohn's disease in pediatric patients presents unique challenges, including the need for treatments that are safe and effective for a developing body. Advances in research have led to tailored therapeutic approaches for children, including age-appropriate medications and nutritional interventions that address both growth and disease management. The growing emphasis on early intervention and personalized care is driving the demand for specialized treatments and support services for pediatric patients.

Asia Pacific Crohn's disease treatment market size will expand substantially through 2032, driven by increasing disease prevalence, improved healthcare infrastructure, and rising awareness of Crohn's disease across the region. The expansion of healthcare access and investment in medical technology are facilitating the availability of advanced treatment options, including biologics and targeted therapies. Additionally, a growing focus on R&D within the region is fostering innovation and enhancing the quality of care. As economic development continues and healthcare systems evolve, the Asia Pacific market is poised for substantial growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of crohn's disease
    • 3.2.1.2 Advancement in diagnostic techniques
    • 3.2.1.3 Increasing research & development activities for drug development
    • 3.2.1.4 Increased awareness about crohn's disease
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Complexity of disease management
    • 3.2.2.2 Lack of curative treatments
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 Anti-inflammatory agents
  • 5.2.2 Immunosuppressants
  • 5.2.3 Antibiotics and antipyretics
  • 5.2.4 Other medications
• 5.3 Nutritional therapy
• 5.4 Surgery

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pediatric
• 7.3 Adult
• 7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals & clinics
• 8.3 Homecare settings
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Amgen Inc.
• 10.3 AstraZeneca Plc
• 10.4 Biogen
• 10.5 Boehringer Ingelheim GmbH
• 10.6 Bristol Myerr Squibb
• 10.7 Eli Lilly and Company
• 10.8 Janssen Pharmaceuticals (Johnson & Johnson)
• 10.9 Merck & Co. Inc
• 10.10 Novartis AG
• 10.11 Pfizer, Inc.
• 10.12 Salix Pharmaceuticals, Inc.
• 10.13 Takeda Pharmaceutical Industries Limited
• 10.14 Viatris Inc. (Mylan N.V.)